Mercer Global Advisors Inc. ADV bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,267 shares of the company’s stock, valued at approximately $207,000.
Other hedge funds have also modified their holdings of the company. Joseph Group Capital Management acquired a new position in shares of Medpace in the 4th quarter worth approximately $535,000. Confluence Wealth Services Inc. acquired a new position in shares of Medpace in the 4th quarter worth approximately $36,000. Signaturefd LLC raised its holdings in shares of Medpace by 486.7% in the 1st quarter. Signaturefd LLC now owns 264 shares of the company’s stock worth $43,000 after buying an additional 219 shares in the last quarter. Lansing Street Advisors acquired a new stake in Medpace during the 1st quarter valued at $44,000. Finally, Prospera Financial Services Inc acquired a new stake in Medpace during the 1st quarter valued at $47,000. 83.97% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Medpace
In other news, CEO August J. Troendle acquired 8,330 shares of the firm’s stock in a transaction on Monday, July 18th. The shares were purchased at an average cost of $145.00 per share, for a total transaction of $1,207,850.00. Following the transaction, the chief executive officer now owns 5,513,639 shares of the company’s stock, valued at $799,477,655. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO August J. Troendle purchased 8,330 shares of Medpace stock in a transaction dated Monday, July 18th. The shares were acquired at an average cost of $145.00 per share, for a total transaction of $1,207,850.00. Following the transaction, the chief executive officer now directly owns 5,513,639 shares of the company’s stock, valued at $799,477,655. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO August J. Troendle purchased 22,290 shares of Medpace stock in a transaction dated Thursday, July 14th. The stock was bought at an average price of $144.59 per share, for a total transaction of $3,222,911.10. Following the completion of the transaction, the chief executive officer now directly owns 5,505,309 shares in the company, valued at $796,012,628.31. The disclosure for this purchase can be found here. Corporate insiders own 20.60% of the company’s stock.
Analyst Upgrades and Downgrades
Medpace Price Performance
MEDP stock opened at $145.55 on Friday. The stock has a market capitalization of $4.51 billion, a price-to-earnings ratio of 25.27 and a beta of 1.43. The business has a fifty day moving average price of $161.03 and a 200 day moving average price of $152.20. Medpace Holdings, Inc. has a fifty-two week low of $126.94 and a fifty-two week high of $231.00.
Medpace (NASDAQ:MEDP – Get Rating) last announced its quarterly earnings data on Monday, July 25th. The company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.12. The firm had revenue of $351.21 million for the quarter, compared to analyst estimates of $344.01 million. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The business’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same period last year, the company earned $1.06 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 6.16 earnings per share for the current fiscal year.
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.